Rhett M. Schiffman, MD, MS, MHSA
Dr. Rhett Schiffman is Vice President of Global Drug Development and Therapeutic Area Head of Ophthalmology at Allergan, Inc.
Dr. Schiffman received his BS in Bioengineering from Columbia University, School of Engineering and Applied Sciences and his MD from the University of Juarez, Mexico.
He completed a residency in Internal Medicine at Henry Ford Hospital and is Board Certified.
While a senior staff physician in the Department of Internal Medicine at Henry Ford Hospital, he completed a Master's Degree in Clinical Research Design and Statistical Analysis at the University of Michigan's School of Public Health.
He was a staff scientist in the Center for Clinical Effectiveness and the Director of General Internal Medicine Research concentrating on decision analysis, clinical policy assessment and medical informatics.
then completed a residency in Ophthalmology and received Board Certification.
also completed a Fellowship in Uveitis and Ocular Immunology at the National Eye Institute of the National Institutes of Health
He returned to Henry Ford Hospital as the Director of Uveitis Services and the Director of Clinical Research where he was Principal Investigator of numerous NIH and Industry funded studies and authored numerous articles and book chapters.
He also received a Master's Degree in Health Services Adminstration from the University of Michigan.
Dr. Schiffman joined Allergan in 2001 and had responsibility for the approval of numerous ophthalmic medications including RESTASIS™, ELESTAT™, ZYMAR™, ZYMAXID™, ACULAR LS™, ACUVAIL™, COMBIGAN™ and LUMIGAN 0.01%™.
He continues to see patients and teach residents at the University of California at Irvine where he is Associate Clinical Professor of Ophthalmology.
Dr. Schiffman joined the Glaucoma Research Foundation Board of Directors in 2010.